NCT00863954

Brief Summary

The purpose of this study is to see if using a device called the Resonator, that puts out a very low electromagnetic field, effects blood glucose and A1c levels in people with Type 2 Diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jan 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 18, 2009

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2009

Completed
Last Updated

December 15, 2010

Status Verified

December 1, 2010

Enrollment Period

10 months

First QC Date

March 17, 2009

Last Update Submit

December 14, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reduction in blood glucose and A1c levels at endpoint compared to start

    Start point, 3 months and 6 months

Study Arms (6)

Output A

ACTIVE COMPARATOR
Device: Resonator Device

Output B

ACTIVE COMPARATOR
Device: Resonator Device

Output C

ACTIVE COMPARATOR
Device: Resonator Device

Output D

ACTIVE COMPARATOR
Device: Resonator Device

Output E

ACTIVE COMPARATOR
Device: Resonator Device

Output F

ACTIVE COMPARATOR
Device: Resonator Device

Interventions

comparison of different parameter settings of electromagnetic fields using the Resonator Device

Output AOutput BOutput COutput DOutput EOutput F

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current diagnosis of Type II Diabetes Mellitus with A1c level above the upper limit of normal
  • Subject currently performs routine finger stick blood sugar testing
  • Subject is ambulatory
  • None or stable medication regimen without significant side effects for at least 6 months, willingness and ability to maintain the stable medication regimen throughout the course of the study.
  • Hemoglobin A1c levels within a 0.8% range of patient mean A1c level for the last two documented determinations, that must be within 2 years of the baseline testing date.
  • Willingness to test finger stick blood sugars according to protocol.
  • Willingness to have lab test blood draws performed according to protocol
  • Willingness to maintain stable diet and activity regimen for the duration of the study.
  • Willing and able to abstain from partaking in any non-essential existing or new treatments to improve serum blood sugar levels.
  • Adequate contraceptive measures for female subjects
  • Male or female
  • Any ethnic group
  • Between 21 and 80 years of age

You may not qualify if:

  • Change in medical regimen within 6 months prior to initiation of study
  • Any signs of Type I diabetes
  • Active infectious process within 3 weeks of study initiation causing wide fluctuations in finger stick blood sugar level.
  • Change in BMI of greater than 6% within a 6 month period prior to study initiation
  • Any planned revascularization procedure
  • Symptomatic congestive heart failure
  • Leg or foot ulceration or open wounds
  • Gangrene
  • History of intermittent claudication
  • Hemodialysis
  • Currently being treated for malignancy
  • Currently being treated with oral or intravenous catabolic steroids.
  • Reported consumption of more than 14 alcoholic drinks per week.
  • Pregnant, breast feeding,or planning pregnancy prior to the end of participation.
  • Developmental disability or cognitive impairment that would make it difficult for the subject to partake in the clinical study, including adequate comprehension of the informed consent form and ability to record the necessary measurements.
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

pico-tesla Magnetic Therapies

Littleton, Colorado, 80120, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 17, 2009

First Posted

March 18, 2009

Study Start

January 1, 2009

Primary Completion

November 1, 2009

Study Completion

November 1, 2009

Last Updated

December 15, 2010

Record last verified: 2010-12

Locations